GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 15:14:06 05/07/2024 BST			5-day change	1st Jan Change
1,511 ^GBX	+0.05%		-1.05%	+4.36%

02:19pm	GSK launches antimalarial drug in Thailand and Brazil	CF
01:59pm	Citigroup Trims GSK PT, Maintains Buy Rating	MT

Gsk PLC - Gsk And Curevac Collaboration Restructured

July 03, 2024 at 07:10 am

GSK plc:

* GSK PLC - GSK AND CUREVAC COLLABORATION RESTRUCTURED

* GSK PLC - ACQUIRES FULL RIGHTS TO DEVELOP VACCINES

* GSK - CUREVAC RECEIVES EUR 400 MILLION UPFRONT AND UP TO AN ADDITIONAL EUR 1.05 BILLION

* GSK - GSK WILL ASSUME FULL CONTROL OF DEVELOPING AND MANUFACTURING CANDIDATE VACCINES

* GSK - ADDITIONAL EUR 1.05 BILLION IN DEVELOPMENT, REGULATORY AND SALES MILESTONES AND TIERED ROYALTIES IN HIGH SINGLE TO LOW TEENS RANGE Source text for Eikon: Further company coverage:

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	GSK PLC	1,514 GBX	+0.25%	-0.77%	78.64B
	CUREVAC N.V.	3.225 USD	+3.37%	-1.47%	700M

Latest news about GSK plc

GSK launches antimalarial drug in Thailand and Brazil	01:19pm	CF
Citigroup Trims GSK PT, Maintains Buy Rating	12:59pm	MT
Jefferies cuts Softcat to 'underperform'	09:16am	AN
GSK : Deutsche Bank keeps its Buy rating	07-04	ZD
GSK : UBS keeps its Buy rating	07-04	ZD
Health Stocks Slip in Risk-On Trade -- Health Care Roundup	07-03	DJ
Sector Update: Health Care Stocks Fall in Afternoon Trading	07-03	MT
Sector Update: Health Care	07-03	MT
European Equities Close Higher in Wednesday Trading; Euro Area Growth Slows to 3-Month Low	07-03	MT
Sector Update: Health Care Stocks Steady Pre-Bell Wednesday	07-03	MT
Looming Holiday Break Stifles US Equity Futures Pre-Bell	07-03	MT
Sector Update: Health Care	07-03	MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Ahead of Economic Data Deluge	07-03	MT
GSK to Buy COVID-19, Flu Vaccine Rights From CureVac for $1.56 Billion	07-03	MT
GSK to Buy CureVac's Covid-19, Flu Vaccine Rights for Up to $1.56 Billion -- 2nd Update	07-03	DJ
Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits	07-03	MT
GSK to Buy CureVac's Covid-19, Flu Vaccine Rights in Up to $1.56 Billion Deal -- Update	07-03	DJ
CureVac Enters Into New Licensing Agreement With GSK; to Implement 'Significant' Restructuring; Shares Rise Pre-Bell	07-03	MT
GSK inks licensing deal with CureVac for flu and Covid drugs	07-03	AN
GSK: collaboration with CureVac in vaccines evolves	07-03	CF
GSK, CureVac Expand Licensing Agreement	07-03	DJ
Keywords Studios agrees takeover by EQT	07-03	AN
GSK and CureVac to Restructure Collaboration into New Licensing Agreement	07-03	CI
GSK Signs New Licensing Deal With CureVac for Influenza, Covid-19 Vaccines	07-03	MT
Gsk PLC - Gsk And Curevac Collaboration Restructured	07-03	RE

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Sector

Pharmaceuticals

Calendar

31/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GSK PLC : Frightened markets create an entry opportunity in GSK

June 04, 2024 at 01:38 pm

GSK plc : Back on track

May 03, 2024 at 10:17 am

More Strategies

Ratings for GSK plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

15.1 GBP

Average target price

20.18 GBP

Spread / Average Target

+33.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GSK PLC	+4.66%	78.64B
ELI LILLY AND COMPANY	+54.56%	809B
NOVO NORDISK A/S	+38.98%	624B
JOHNSON & JOHNSON	-7.35%	351B
ABBVIE INC.	+5.96%	289B
ASTRAZENECA PLC	+13.79%	240B
NOVARTIS AG	+14.23%	220B
ROCHE HOLDING AG	+0.04%	219B
AMGEN INC.	+7.74%	166B
PFIZER, INC.	-3.66%	157B

Other Pharmaceuticals

GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Gsk PLC - Gsk And Curevac Collaboration Restructured

Stocks mentioned in the article

Latest news about GSK plc

Chart GSK plc

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for GSK plc

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals